Zimmer Biomet Holdings (ZBH) Cash & Equivalents (2009 - 2026)

Zimmer Biomet Holdings' Cash & Equivalents history runs 18 years deep, the most recent figure standing at $424.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 69.36% year-over-year to $424.2 million; the TTM figure through Mar 2026 stood at $424.2 million (down 69.36% YoY), while the FY2025 annual figure was $591.9 million, up 12.64% from the prior year.
• Cash & Equivalents was $424.2 million for Q1 2026 at Zimmer Biomet Holdings, down from $591.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.4 billion in Q1 2025 to a low of $292.1 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $544.6 million across 5 years, with a median of $424.2 million in 2026.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents soared 252.29% in 2025, then sank 69.36% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $375.7 million in 2022, then climbed by 10.67% to $415.8 million in 2023, then rose by 26.38% to $525.5 million in 2024, then climbed by 12.64% to $591.9 million in 2025, then decreased by 28.33% to $424.2 million in 2026.
• The last three Cash & Equivalents figures came in at $424.2 million (Q1 2026), $591.9 million (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.